공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 암용 생물학적 독소 의약품 시장 : 기회, 치료제 매출, 임상시험 인사이트(-2026년)

Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026

리서치사 KuicK Research
발행일 2021년 02월 상품 코드 985629
페이지 정보 영문 330 Pages
가격
US $ 2,400 ₩ 2,712,000 Unprintable PDF (Single User License)
US $ 4,200 ₩ 4,747,000 Printable PDF (Multi-User License)


세계의 암용 생물학적 독소 의약품 시장 : 기회, 치료제 매출, 임상시험 인사이트(-2026년) Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026
발행일 : 2021년 02월 페이지 정보 : 영문 330 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

암용 생물학적 독소 의약품 시장은 지속가능한 결과 달성 및 향후 암 치료 상황을 변화시키는 광범위한 응용에 의해 긍정적인 전망을 보이고 있습니다.

주요 시장 성장요인으로서 암 환자 증가, 암 사망률 증가 암에 대한 생물학적 독소 이용에 관한 의식 고양, 시장에서 이용 가능한 기타 치료법의 높은 실패율 등을 들 수 있습니다.

세계의 암용 생물학적 독소 의약품(Cancer Biological Toxins Drug) 시장에 대해 조사분석했으며, 시장 개요, 암 관리에서 생물학적 독소의 역할, 암을 표적으로 하는 생물학적 독소의 종류, 암용 생물학적 독소 시장 성장이 기타 암 치료제에 미치는 영향, 각종 암용 생물학적 독소, 연구 동향, 임상 파이프라인, 주요 기업 등에 대해 전해드립니다.

목차

제 1장 생물학적 독소 서론

  • 개요
  • 강력한 항암 치료제로서의 생물학적 독소 진화

제2장 암 관리에서 생물학적 독소의 역할

제3장 암을 표적으로 하는 생물학적 독소의 종류

  • Single Chain Biological Toxins
  • Pore Forming Toxins
  • Anthrax Toxins

제4장 암용 생물학적 독소 시장 성장이 기타 시행 가능한 암 치료제에 미치는 영향

  • 세계 암 면역치료 시장에 대한 생물학적 독소 치료제 시장의 영향
    • 암용 생물학적 독소 치료제 vs. 면역 체크포인트 저해제 요법
    • 암용 생물학적 독소 치료제 vs. 면역치료 단클론항체
    • 암용 생물학적 독소 치료제 vs. 암 백신 시장
  • 세계 암 생물학적 독소요법 시장이 과거 &전통적인 암치료에 미치는 영향
    • 암용 생물학적 독소 치료제 vs. 암 환자용 화학요법
    • 암용 생물학적 독소 치료제 vs. 암 치료용 방사선 요법
    • 암용 생물학적 독소 치료제 vs. 암 치료용 외과 수술

제5장 뇌종양용 생물학적 독소

  • 뇌종양 표적화에 사용되는 독소
  • 뇌종양에 대한 녹농균외 독소 기반 면역 독소
    • IL4-PE
    • IL13-PE
    • TP-38
  • 뇌종양에 대한 디프테리아 독소 기반 면역 독소
    • Tf-CRM107
    • DTAT&DTAT13
  • 뇌종양을 표적으로 하기 위한 항원
    • 트랜스페린 수용체
    • Interleukin-4 수용체
    • Interleukin-13 수용체
    • 표피성장인자 수용체
    • 기타 항원

제6장 혈액 종양에 대한 생물학적 독소

  • 백혈병 및 림프종에서 생물학적 독소의 역할
  • 진행중인 연구개발

제7장 고형암 표적화에 사용되는 생물학적 독소

  • 고형암 치료에 대한 영향
  • 진행중인 연구&진보

제8장 유방암용 생물학적 독소

  • 유방암에서의 생물학적 독소 응용
  • 진행중인 개발

제9장 폐암용 생물학적 독소

  • 역할과 응용
  • 최근의 연구개발

제10장 기타 암용 생물학적 독소

  • 전립선암
  • 흑색종
  • 결장직장암
  • 부인과암
  • 소화기암

제11장 세계의 면역 독소 시장 : 가용성, 투여량, 특허, 가격 분석

  • Lumoxiti(Moxetumomab pasudotox)

제12장 암용 생물학적 독소시장 을 위한 연구&의학적 진보

  • UCLA 연구자는 Diazonaangulata(어개류) 유래 단백질을 사용해 암 부작용을 최소한으로 억제한다
  • 환자 위암 세포에 대해서 유효한 보툴리눔톡신(보톡스)
  • 식도암 치료 후 합병증을 극적으로 경감하는 보툴리눔톡신(보톡스) A
  • 보다 좋은 결과를 나타내는 피부 평활근종에 대한 보툴리눔톡신(보톡스) A
  • 진행성 고형 암 치료 을 위한 TR1801-ADC 특성 평가
  • 화학요법과 방사선 요법 유효성을 높이는 보툴리눔톡신(보톡스)
  • 보툴리눔톡신(보톡스) A는 유방암 수술 후 지속성 통증을 치료
  • 새롭게 발견된 보툴리눔톡신(보톡스) X는 암이나 기타 병 치료에 도움이 될 가능성

제13장 암용 생물학적 독소 : 임상시험 통찰

  • 단계별
  • 현황별
  • 암종류별
  • 국가별

제14장 세계 암용 생물학적 독소 임상 파이프라인 : 기업·적응증·단계별

  • 연구
  • 전임상
  • 단계 I
  • 단계 I / II
  • 단계 II
  • 단계 II / III
  • 단계 III
  • 사전 등록
  • 등록이 끝난 상태

제15장 시판 암용 생물학적 독소 임상적 통찰 : Moxetumomab Pasudotox(Lumoxiti)

제16장 세계의 암용 생물학적 독소 치료제 시장 역학

  • 유리한 시장 파라미터
  • 시장이 해결해야 할 과제

제17장 암용 생물학적 독소 시장의 향후 방향성

제18장 경쟁 구도

  • Angimmune
  • Eisai
  • Molecular Template(mTEM)
  • Astrazeneca
  • Research Corporation Technologies
  • Sanofi
  • Seattle Genetics
  • Roche
  • Neopharma
  • Xenova Biomedix
LSH 21.02.08

List of Figures

  • Figure 1-1: Evolution of Biological Toxins as Anticancer Therapeutics
  • Figure 2-1: Management of Biological Toxins in Cancer Treatment
  • Figure 3-1: Components of Immunotoxins
  • Figure 3-2: Components of Targeted Toxins
  • Figure 3-3: Types of Cancer Targeting Biological Toxins
  • Figure 3-4: Structure of Diphtheria Toxin & Denileukin diftitox (Ontak)
  • Figure 3-5: Mechanism of Denileukin diftitox (Ontak)
  • Figure 3-6: Mechanism of Pore Forming Biological Toxins
  • Figure 4-1: Cancer Biological Toxins Vs. Monoclonal Antibody
  • Figure 4-2: Old & Traditional Cancer Therapies Available in Therapeutics Market
  • Figure 4-3: Cancer Biological Toxin Therapy Action Vs. Chemotherapy Drug Action
  • Figure 4-4: Cancer Biological Toxin Vs. Surgical Removal of Cancer Cells
  • Figure 5-1: Commonly used Biological Toxins for Targeting Brain Tumor
  • Figure 5-2: Pseudomonas Exotoxin Based Immunotoxins
  • Figure 5-3: Diphtheria Toxin Based Immunotoxins under Development Phase
  • Figure 5-4: Antigens/ Receptors for Targeting Brain Tumor
  • Figure 5-5: Cintredekin Besudotox - Orphan Drug Designation Year by Indication
  • Figure 5-6: D2C7-IT Trial - Trial Initiation & Expected Completion Year
  • Figure 5-7: Role of Urokinase-Type Plasminogen Activator Receptor in Brain Tumor
  • Figure 6-1: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
  • Figure 6-2: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
  • Figure 6-3: Commonly used Biological Toxins for Targeting Haematological Tumor
  • Figure 6-4: Target Receptor for Ontak
  • Figure 6-5: Resimmune - FDA Orphan Designation & Fast Track Designation Year
  • Figure 6-6: Immunotoxin Receptors for Haematological Cancer
  • Figure 6-7: Investigational Immunotoxins for Haematological Cancer
  • Figure 6-8: Mechanism of LMB2 against Cells of Hematological Tumors
  • Figure 6-9: LMB-2 Phase II Trial - Study Initiation & Expected Completion Year
  • Figure 6-10: LMB-2 Phase I/II Trial - Study Initiation & Expected Completion Year
  • Figure 6-11: BL22 (CAT-3888) - Mechanism of Action against Hematological Malignancy
  • Figure 6-12: DT388GMCSF: Mechanism of Action Against Leukemia Cells
  • Figure 6-13: Resimmune - Mechanism of Action Against Cutaneous T Cell Lymphoma
  • Figure 6-14: Mechanism of MT-3724 in Hematological Cancer
  • Figure 6-15: MT-3724 Phase I/II Trial - Study Initiation & Expected Completion Year
  • Figure 6-16: MT-3724 Phase II Trial - Study Initiation & Expected Completion Year
  • Figure 7-1: Biological Toxins for Targeting Solid Tumors
  • Figure 7-2: Limitations of Immunotoxins in Solid Tumors
  • Figure 7-3: Immunotoxin for Solid Tumors by Target Receptor
  • Figure 7-4: Investigational Immunotoxins for Solid Tumor
  • Figure 7-5: SS1P - Mechanism of Action against Solid Tumor
  • Figure 7-6: LMB-100 - Mechanism of Action against Solid Tumors
  • Figure 7-7: LMB-100 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 7-8: LMB-100 Phase I/II Trial - Study Initiation & Expected Completion Year
  • Figure 7-9: LMB-7 - Mechanism of Action against Solid Tumors
  • Figure 8-1: Global - Newly Diagnosed Cases & Deaths related to Breast Cancer (Million), 2020
  • Figure 8-2: Biological Toxins Used for Targeting Breast Cancer
  • Figure 8-3: Approaches Used to Overcome Immunogenicity
  • Figure 8-4: Investigational Immunotoxins for Breast Cancer
  • Figure 9-1: Global - Newly Diagnosed Cases & Deaths related to Lung Cancer (Million), 2020
  • Figure 9-2: Biological Toxins used for Targeting Lung Cancer
  • Figure 9-3: Antigens/Receptors Expressed Over Lung Cancer Cells
  • Figure 9-4: Investigational Immunotoxins for Lung Cancer
  • Figure 10-1: Global - Newly Diagnosed Cases & Deaths related to Prostate Cancer (Million), 2020
  • Figure 10-2: Commonly used Biological Toxins for Targeting Prostate Cancer
  • Figure 10-3: Role of A-dmDT390-ScfbDb(PSMA) in Prostate Cancer
  • Figure 10-4: Investigational Immunotoxins for Prostate Cancer
  • Figure 10-5: Global - Newly Diagnosed Cases & Deaths related to Melanoma, 2020
  • Figure 10-6: Mechanism of PE Based Immunotoxins against Melanoma Cells
  • Figure 10-7: Antigens/Receptors Expressed Over Melanoma Cells
  • Figure 10-8: Mechanism of 9.2.27PE
  • Figure 10-9: Global - Newly Diagnosed Cases & Deaths related to Colon Cancer (Million), 2020
  • Figure 10-10: Global - Newly Diagnosed Cases & Deaths related to Rectum Cancer (Million), 2020
  • Figure 10-11: Antigens/Receptors Expressed Over Cells of Colorectal Cancer
  • Figure 10-12: Investigational Immunotoxins for Colorectal Cancer
  • Figure 10-13: BM7PE Trial - Study Initiation & Expected Completion Year
  • Figure 10-14: Global - Number of Newly Diagnosed Cases of Leading Gynecological Cancer, 2020
  • Figure 10-15: Global - Number of Deaths by Leading Gynecological Cancer, 2020
  • Figure 10-16: Antigens/Receptors Expressed Over Cells of Gynecological Cancers
  • Figure 10-17: Investigational Immunotoxins for Gynecological Cancer
  • Figure 10-18: Global - Number of Newly Diagnosed Cases of Leading Gastrointestinal Cancer, 2020
  • Figure 10-19: Global - Number of Deaths by Leading Gastrointestinal Cancer, 2020
  • Figure 10-20: Antigens/Receptors Expressed Over Cells of Gastrointestinal Cancers
  • Figure 10-21: Investigational Immunotoxins for Gastrointestinal Cancer
  • Figure 10-22: LMB-100 Phase Ib/II Trial - Study Initiation & Expected Completion Year
  • Figure 10-23: LMB-100 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 11-1: Lumoxiti - Year of Orphan Designation, FDA Approval & Patent Expiration
  • Figure 11-2: Lumoxiti - Duration of Single Treatment Cycle & Full Treatment (Weeks), January'2021
  • Figure 11-3: Lumoxiti - Number of Dose Required in Single Treatment Cycle & Full Treatment, January'2021
  • Figure 11-4: Lumoxiti - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), January'2021
  • Figure 13-1: Global - Number of Cancer Biological Toxins Related Clinical Trials by Phase, January'2021
  • Figure 13-2: Global - Cancer Biological Toxins Related Clinical Trials by Phase (%), January'2021
  • Figure 13-3: Global - Number of Cancer Biological Toxins Related Clinical Trials by Status, January'2021
  • Figure 13-4: Global - Cancer Biological Toxins Related Clinical Trials by Status (%), January'2021
  • Figure 13-5: Global - Number of Cancer Biological Toxins Related Clinical Trials by Indication, January'2021
  • Figure 13-6: Global - Cancer Biological Toxins Related Clinical Trials by Indication (%), January'2021
  • Figure 13-7: Global - Number of Cancer Biological Toxins Related Clinical Trials by Region, January'2021
  • Figure 13-8: Global - Number of Cancer Biological Toxins Related Phase I Clinical Trials by Region, January'2021
  • Figure 13-9: Global - Number of Cancer Biological Toxins Related Phase I-II Clinical Trials by Region, January'2021
  • Figure 13-10: Global - Number of Cancer Biological Toxins Related Phase I-II Clinical Trials by Region, January'2021
  • Figure 16-1: Drivers for the Growth of Cancer Biological Toxin Market
  • Figure 17-1: Global - Cancer Biological Toxins Expected Market Opportunity (US$ Million), 2021 -2026
  • Figure 17-2: Parameters Driving the Future Insight for Cancer Biological Toxin Market

"Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:

  • Cancer Biological Toxins Clinical Trials: >70 Drugs in Pipeline
  • Global Cancer Biological Toxins Expected Market Opportunity: > US$ 200 Million
  • Biological Toxins Drug Insight by Cancer
  • Cancer Biological Toxins Clinical Trial Insight by Phase, Status, Cancer & Country
  • Marketed Cancer Biological Toxin Clinical Insight: Moxetumomab Pasudotox (Lumoxiti)

The fast pace of cancer prevalence and mortality rate across the globe has led to an increasing concern as well as recognition that the specific disease requires attention by the researchers. In the past few years, the type of research activities that have been conducted for cancer disease has moved several laboratory findings to the commercial world. In one of the scenarios, development of cancer biological toxins is a form of novel technology facility resulted from the translational research conducted at different research centers. The therapy developed and re-defined by hundreds of researchers in the past few years is witnessed to facilitate promising cancer targets in its preclinical as well as clinical research. The comprehensive outlook for the market appears to the positive, in terms of sustainable results achieved and its wide range applications to alter the future cancer therapeutics landscape.

While hundreds of other cancer therapies are failing to stake their applications in treating cancer patients, cancer biological toxin therapy is caught in the middle to get recognized as an offering that is unimaginable. The market since its emergence has remained ahead with respect to the overall survival rate it is delivering as well as solving the entire healthcare problems related with cancer development and progression. Several drug makers in today's world are getting involved in boosting the value chain of the market by delivering conventional thinking and re-defining the entire role of their research and development sector for the market expansion.

The market since its arrival in the cancer therapeutics market at global level has remained successful in reconfiguring today's cancer challenges by causing a shift from only being a therapy to becoming one of the standard healthcare regimens for millions of patients. All this is inclining the market towards poised growth, where in the next few years, the market will observe an influx in the market size by huge percentage. The several highlights of the market are also projecting increase in demand of the drug products available under it as the disease lifestyle is becoming more prevalent, thus making the researchers unlock more hidden potential of the therapy for different cancer patient types.

Traditionally, the cancer biological toxin market is prone to deliver and provide value in terms of complete eradication of the cancer cells by performing splendid research and development activities. But an important reason that has led to substantial rise in the clinical and research activities related with cancer is the overhaul that the other available cancer therapies had created for the past many decades. This resulted in the foundational shift in the entire cancer therapeutics industry and thus, the emergence of therapy that involves toxins isolated from prokaryotes for killing the cancer cells. To date, researchers have been successful in isolating and studying the expression of biological toxins from different organisms for killing cancer cells but one most studied bacterium for the therapy is Clostridium botulinum.

The respective bacterium and several others have promised highest returns for the cancer patients. Also, the toxins isolated from such living organisms and their transformation into drug products have led to the representation of the therapy in top best-selling cancer therapies at global level. The market due to several ongoing processes and certain achievements of the past is expected to continue to observe strong growth, with a CAGR rate of double-digit. There are numerous parameters that are associated with the market and acting as drivers. Some of the driving forces for the market are: increase in cancer cases, increase in cancer mortality rate, increase in awareness about the applications of cancer biological toxins and high failure rate of other therapies available in the market.

The unexpected status of the cancer biological toxin market has also resulted in challenging the business model of other therapies. The market's growing research spending amount and involvement of leading players of the pharmaceutical industry are also causing a robust demonstration of the applications and wide healthcare opportunities associated with the market. In addition, the therapy market is being measured as a superior therapy carrying all parameters for getting classified as a standard of care rather than just a usual cancer therapy for the patients. The healthy outcomes associated with the market are also directly linking the market to hedge over the highly expensive market such as chemotherapy, immunotherapy or any other combination therapy.

Table of Contents

1. Introduction to Biological Toxins

  • 1.1 Overview
  • 1.2 Evolution of Biological Toxins as Potent Anticancer Therapeutics

2. Role of Biological Toxins in Cancer Management

3. Types of Biological Toxins for Targeting Cancer

  • 3.1 Single Chain Biological Toxins
  • 3.2 Pore Forming Toxins
  • 3.3 Anthrax Toxins

4. Impact of Growing Cancer Biological Toxin Market on Other Viable Cancer Therapies

  • 4.1 Global Impact of Cancer Biological Toxin Therapy Market on Cancer Immunotherapy Market
    • 4.1.1 Cancer Biological Toxin Therapy Vs. Immune Checkpoint Inhibitor Therapy
    • 4.1.2 Cancer Biological Toxin Therapy Vs. Immunotherapy Monoclonal Antibodies
    • 4.1.3 Cancer Biological Toxins Therapy Market Vs. Cancer Vaccine Market
  • 4.2 Global Impact of Cancer Biological Toxin Therapy Market on Old & Traditional Cancer Therapies
    • 4.2.1 Cancer Biological Toxin Therapy Market Vs. Chemotherapy for Cancer Patients
    • 4.2.2 Cancer Biological Toxin Therapy Market Vs. Radiation Therapy for Cancer Treatment
    • 4.2.3 Cancer Biological Toxin Therapy Vs. Surgical Procedure for Cancer Treatment

5. Biological Toxins for Brain Tumors

  • 5.1 Toxins Used for Targeting Brain Tumors
  • 5.2 Pseudomonas Exotoxin-Based Immunotoxins for Brain Tumors
    • 5.2.1 IL4-PE
    • 5.2.2 IL13-PE
    • 5.2.3 TP-38
  • 5.3 Diphtheria Toxin-Based Immunotoxins for Brain Tumor
    • 5.3.1 Tf-CRM107
    • 5.3.2 DTAT & DTAT13
  • 5.4 Antigens for Targeting Brain Tumor
    • 5.4.1 Transferrin Receptor
    • 5.4.2 Interleukin-4 Receptor
    • 5.4.3 Interleukin-13 Receptor
    • 5.4.4 Epidermal Growth Factor Receptor
    • 5.4.5 Other Antigens

6. Biological Toxins Against Hematological Tumors

  • 6.1 Role of Biological Toxins in Leukemia & Lymphoma
  • 6.2 Ongoing Research & Development

7. Biological Toxins For Targeting Solid Tumors

  • 7.1 Impact on Solid Tumor Treatment
  • 7.2 Ongoing Research & Advancements

8. Biological Toxins for Breast Cancer

  • 8.1 Application of Biological Toxins in Breast Cancer
  • 8.2 Ongoing Development

9. Biological Toxins for Lung Cancer

  • 9.1 Role & Applications
  • 9.2 Recent Research & Development

10. Biological Toxins For Other Cancers

  • 10.1 Prostate Cancer
  • 10.2 Melanoma
  • 10.3 Colorectal Cancer
  • 10.4 Gynecological Cancer
  • 10.5 Gastrointestinal Cancers

11. Global Immunotoxin Market - Availability, Dosage, Patent & Price Analysis

  • 11.1 Lumoxiti (Moxetumomab pasudotox)

12. Research & Medical Advancement for Cancer Biological Toxin Market

  • 12.1 UCLA Researchers to Minimize Cancer Side Effects by Using Protein Derived from Diazona angulata
  • 12.2 Botulinum Toxin Effective against Stomach Cancer Cells in the Patients
  • 12.3 Botulinum Toxin A to Drastically Reduce Complications After Esophageal Cancer Treatment
  • 12.4 Botulinum Toxin A against Cutaneous Leiomyomas Indicating for Better Results
  • 12.5 TR1801-ADC Characterization for the Treatment of Advanced Solid Cancer
  • 12.6 Botulinum Toxin to Increase the Effectiveness of Chemotherapy & Radiation Therapy
  • 12.7 Botulinum Toxin A Cure for Persistent Pain after Breast Cancer Surgery
  • 12.8 Newly Discovered Botulinum Toxin X to have Potential for Treating Cancer & Other Diseases

13. Cancer Biological Toxins - Clinical Trial Insight

  • 13.1 By Phase
  • 13.2 By Status
  • 13.3 By Cancer Type
  • 13.4 By Countries

14. Global Cancer Biological Toxins Clinical Pipeline By Company, Indication & Phase

  • 14.1 Research
  • 14.2 Preclinical
  • 14.3 Phase-I
  • 14.4 Phase-I/II
  • 14.5 Phase-II
  • 14.6 Phase-II/III
  • 14.7 Phase-III
  • 14.8 Preregistration
  • 14.9 Registered

15. Marketed Cancer Biological Toxin Clinical Insight: Moxetumomab Pasudotox (Lumoxiti)

16. Global Cancer Biological Toxin Therapeutics Market Dynamics

  • 16.1 Favourable Market Parameters
  • 16.2 Market Challenges

17. Future Directions for Cancer Biological Toxin Market

18. Competitive Landscape

  • 18.1 Angimmune
  • 18.2 Eisai
  • 18.3 Molecular Template (mTEM)
  • 18.4 Astrazeneca
  • 18.5 Research Corporation Technologies
  • 18.6 Sanofi
  • 18.7 Seattle Genetics
  • 18.8 Roche
  • 18.9 Neopharma
  • 18.10 Xenova Biomedix
Back to Top
전화 문의
F A Q